258 related articles for article (PubMed ID: 15027078)
21. A Bayesian predictive two-stage design for phase II clinical trials.
Sambucini V
Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
[TBL] [Abstract][Full Text] [Related]
22. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
23. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
24. Design and analysis of phase I clinical trials.
Storer BE
Biometrics; 1989 Sep; 45(3):925-37. PubMed ID: 2790129
[TBL] [Abstract][Full Text] [Related]
25. An improved method of evaluating drug effect in a multiple dose clinical trial.
Shen L
Stat Med; 2001 Jul; 20(13):1913-29. PubMed ID: 11427949
[TBL] [Abstract][Full Text] [Related]
26. Improved confidence intervals for a binomial parameter following a group sequential phase II clinical trial.
Chang MN
Stat Med; 2004 Sep; 23(18):2817-26. PubMed ID: 15344188
[TBL] [Abstract][Full Text] [Related]
27. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Resche-Rigon M; Zohar S; Chevret S
Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
[TBL] [Abstract][Full Text] [Related]
28. Interval estimation of risk ratio in the simple compliance randomized trial.
Lui KJ
Contemp Clin Trials; 2007 Feb; 28(2):120-9. PubMed ID: 16820329
[TBL] [Abstract][Full Text] [Related]
29. Adaptive designs for confirmatory clinical trials.
Bretz F; Koenig F; Brannath W; Glimm E; Posch M
Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
[TBL] [Abstract][Full Text] [Related]
30. Confidence limits for probability of response in multistage phase II clinical trials.
Atkinson EN; Brown BW
Biometrics; 1985 Sep; 41(3):741-4. PubMed ID: 4074823
[TBL] [Abstract][Full Text] [Related]
31. Small-sample estimation of negative binomial dispersion, with applications to SAGE data.
Robinson MD; Smyth GK
Biostatistics; 2008 Apr; 9(2):321-32. PubMed ID: 17728317
[TBL] [Abstract][Full Text] [Related]
32. Bivariate sequential designs for phase II trials.
Conaway MR; Petroni GR
Biometrics; 1995 Jun; 51(2):656-64. PubMed ID: 7662852
[TBL] [Abstract][Full Text] [Related]
33. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
34. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
35. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
Salim A; Mackinnon A; Christensen H; Griffiths K
Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
[TBL] [Abstract][Full Text] [Related]
36. Samples of exact k-stage group sequential designs for Phase II and Pilot studies.
Kepner JL; Chang MN
Control Clin Trials; 2004 Jun; 25(3):326-33. PubMed ID: 15157732
[TBL] [Abstract][Full Text] [Related]
37. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
38. Likelihood inference for a two-stage design with treatment selection.
Bebu I; Luta G; Dragalin V
Biom J; 2010 Dec; 52(6):811-22. PubMed ID: 20818645
[TBL] [Abstract][Full Text] [Related]
39. A composite design for transition from a preliminary to a full-scale study.
Lachin JM; Younes N
Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
[TBL] [Abstract][Full Text] [Related]
40. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
Schlesselman JJ; Reis IM
Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
